CN1152691C - 使用经过化学稳定的亚氯酸盐溶液用于抑制抗原特异性的免疫反应的用途 - Google Patents
使用经过化学稳定的亚氯酸盐溶液用于抑制抗原特异性的免疫反应的用途 Download PDFInfo
- Publication number
- CN1152691C CN1152691C CNB988118858A CN98811885A CN1152691C CN 1152691 C CN1152691 C CN 1152691C CN B988118858 A CNB988118858 A CN B988118858A CN 98811885 A CN98811885 A CN 98811885A CN 1152691 C CN1152691 C CN 1152691C
- Authority
- CN
- China
- Prior art keywords
- antigen
- cell
- disease
- application described
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
所测量的参数 | p-值* | 方向 |
CD3+,CD8+,CD28- | 0.027 | 增加 |
CD14+,TNF- | 0.017 | 减少 |
CD14-,DR+ | 0.032 | 减少 |
CD3+,CD4+,CD38+(MF CD38抗原) | 0.021 | 减少 |
CD3+,CD8+,CD28+(MF CD28抗原) | 0.010 | 减少 |
CD20+,DR+(MF DR抗原) | 0.014 | 减少 |
所有的CD14+ | 0.037 | 减少 |
Claims (26)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6095397P | 1997-10-06 | 1997-10-06 | |
US60/060953 | 1997-10-06 | ||
US60/060,953 | 1997-10-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1306433A CN1306433A (zh) | 2001-08-01 |
CN1152691C true CN1152691C (zh) | 2004-06-09 |
Family
ID=22032774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988118858A Expired - Fee Related CN1152691C (zh) | 1997-10-06 | 1998-10-06 | 使用经过化学稳定的亚氯酸盐溶液用于抑制抗原特异性的免疫反应的用途 |
Country Status (12)
Country | Link |
---|---|
US (4) | US20050129784A1 (zh) |
EP (1) | EP1021196B1 (zh) |
JP (1) | JP4369615B2 (zh) |
CN (1) | CN1152691C (zh) |
AT (1) | ATE258799T1 (zh) |
AU (1) | AU754928B2 (zh) |
CA (1) | CA2306273A1 (zh) |
DE (1) | DE69821506T2 (zh) |
DK (1) | DK1021196T3 (zh) |
ES (1) | ES2217582T3 (zh) |
PT (1) | PT1021196E (zh) |
WO (1) | WO1999017787A2 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6913200A (en) * | 1999-08-18 | 2001-03-13 | Oxo Chemie Ag | Chemically-stabilized chlorite solutions for treating cancer and other diseases |
US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
AU2011205095B2 (en) * | 2004-02-03 | 2014-07-03 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
EP1979269A4 (en) | 2005-12-22 | 2013-01-02 | Taiji Biomedical Inc | CHLORINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF |
WO2008145376A1 (en) * | 2007-06-01 | 2008-12-04 | Dimethaid Ag | Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
EA201290041A1 (ru) * | 2009-08-06 | 2012-07-30 | Ньюралтус Фармасьютикалс, Инк. | Лечение расстройств, связанных с макрофагами |
WO2011059926A2 (en) | 2009-11-10 | 2011-05-19 | Mayo Foundation For Medical Eduction And Research | Methods and materials for treating renal cell carcinoma |
RU2014130080A (ru) | 2011-12-22 | 2016-02-10 | Нуво Рисерч Гмбх | Липосомальные композиции хлоритов или хлоратов |
WO2013109949A1 (en) * | 2012-01-19 | 2013-07-25 | Ibt Usa Inc. | Therapeutic uses of tetrachlorodecaoxygen (tcdo) |
WO2014078272A1 (en) | 2012-11-13 | 2014-05-22 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing immune system profiles |
US10094835B2 (en) | 2013-05-09 | 2018-10-09 | Mayo Foundation For Medical Education And Research | Treating patients based on immune subtypes |
JP6900596B2 (ja) * | 2015-08-20 | 2021-07-07 | フリードリッヒ − ヴィルヘルム キューネ | 赤血球疾患およびそれによって媒介される症状を治療するための亜塩素酸塩の使用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4574084A (en) * | 1983-02-25 | 1986-03-04 | Peter Berger | Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof |
DE3515749A1 (de) * | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Verwendung einer stabilisierten chloritmatrixloesung bei infektioesen zustaenden |
DE3515745A1 (de) * | 1985-05-02 | 1986-11-06 | Oxo Chemie GmbH, 6900 Heidelberg | Waessrige chloritmatrix-loesung |
US4851222A (en) * | 1988-01-27 | 1989-07-25 | Oxo Chemie Gmbh | Method of promoting regeneration of bone marrow |
US4956184A (en) * | 1988-05-06 | 1990-09-11 | Alcide Corporation | Topical treatment of genital herpes lesions |
DE4208828A1 (de) * | 1992-03-19 | 1993-09-23 | Oxo Chemie Gmbh | Verwendung einer chemisch stabilisierten chloritmatrix zur herstellung von arzneimitteln zur behandlung von hiv-infektionen |
US5830511A (en) * | 1992-06-25 | 1998-11-03 | Bioxy Inc. | Therapeutic, production and immunostimulatory uses of biocidal compositions |
US5877222A (en) * | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
WO2008145376A1 (en) * | 2007-06-01 | 2008-12-04 | Dimethaid Ag | Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
-
1998
- 1998-10-06 AU AU93642/98A patent/AU754928B2/en not_active Ceased
- 1998-10-06 AT AT98946681T patent/ATE258799T1/de active
- 1998-10-06 ES ES98946681T patent/ES2217582T3/es not_active Expired - Lifetime
- 1998-10-06 DK DK98946681T patent/DK1021196T3/da active
- 1998-10-06 PT PT98946681T patent/PT1021196E/pt unknown
- 1998-10-06 EP EP98946681A patent/EP1021196B1/en not_active Expired - Lifetime
- 1998-10-06 CN CNB988118858A patent/CN1152691C/zh not_active Expired - Fee Related
- 1998-10-06 WO PCT/IB1998/001676 patent/WO1999017787A2/en active IP Right Grant
- 1998-10-06 CA CA002306273A patent/CA2306273A1/en not_active Abandoned
- 1998-10-06 JP JP2000514658A patent/JP4369615B2/ja not_active Expired - Fee Related
- 1998-10-06 DE DE69821506T patent/DE69821506T2/de not_active Expired - Lifetime
-
2004
- 2004-07-22 US US10/895,941 patent/US20050129784A1/en not_active Abandoned
-
2008
- 2008-06-04 US US12/132,761 patent/US20090004295A1/en not_active Abandoned
-
2010
- 2010-09-30 US US12/894,618 patent/US20110076344A1/en not_active Abandoned
-
2012
- 2012-02-06 US US13/366,595 patent/US20120141514A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20090004295A1 (en) | 2009-01-01 |
WO1999017787A2 (en) | 1999-04-15 |
ATE258799T1 (de) | 2004-02-15 |
US20050129784A1 (en) | 2005-06-16 |
US20120141514A1 (en) | 2012-06-07 |
US20110076344A1 (en) | 2011-03-31 |
EP1021196A2 (en) | 2000-07-26 |
DE69821506D1 (de) | 2004-03-11 |
DK1021196T3 (da) | 2004-06-07 |
AU9364298A (en) | 1999-04-27 |
ES2217582T3 (es) | 2004-11-01 |
PT1021196E (pt) | 2004-06-30 |
JP2001518512A (ja) | 2001-10-16 |
CA2306273A1 (en) | 1999-04-15 |
CN1306433A (zh) | 2001-08-01 |
WO1999017787A3 (en) | 1999-06-17 |
AU754928B2 (en) | 2002-11-28 |
EP1021196B1 (en) | 2004-02-04 |
JP4369615B2 (ja) | 2009-11-25 |
DE69821506T2 (de) | 2004-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1152691C (zh) | 使用经过化学稳定的亚氯酸盐溶液用于抑制抗原特异性的免疫反应的用途 | |
Chang et al. | Anti‐IgE antibodies for the treatment of IgE‐mediated allergic diseases | |
Hauben et al. | Therapeutic vaccination for spinal cord injury: helping the body to cure itself | |
Nakae et al. | Mast cell–derived TNF can promote Th17 cell–dependent neutrophil recruitment in ovalbumin-challenged OTII mice | |
Wang et al. | Cellular nanosponges for biological neutralization | |
EP2399595B1 (en) | Immunopotentiating composition and process for producing same | |
Willis et al. | Interleukin-7 receptor blockade suppresses adaptive and innate inflammatory responses in experimental colitis | |
Ballow et al. | Immune response modifiers in the treatment of asthma: A PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology | |
Mizrahi et al. | Citrus Oil and MgCl2 as Antibacterial and Anti‐Inflammatory Agents | |
Nüssler et al. | Immunomodulatory agents in the laboratory and clinic | |
CN1331477C (zh) | 药用纳米碳管组合物、制备方法及其应用 | |
CN1129453C (zh) | 用于下调免疫系统Th2活性的母牛分枝杆菌 | |
Fukuda et al. | Oral immunotherapy for allergic conjunctivitis using transgenic rice expressing hypoallergenic antigens | |
CN1378456A (zh) | 用于治疗癌症和其它疾病的化学稳定化亚氯酸盐溶液 | |
Kumar et al. | Future prospects of biologic therapies for immunologic diseases | |
Potter et al. | Review‐The Use of Immunosuppressive Agents to Prevent Neutralizing Antibodies Against a Transgene Product | |
RU2804298C1 (ru) | Противолучевая композиция на основе хитино-глюканового комплекса гриба вешенки обыкновенной | |
Budde et al. | Dendritic polyglycerol sulfate attenuates murine graft-versus-host disease | |
Baron et al. | Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation | |
KR20220016104A (ko) | 암 치료를 위한 프로카스파아제-3 활성화 및 면역요법 | |
DATE et al. | Gamifant (emapalumab-lzsg) Policy Number: C15970-A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: DIMISIDE LTD. Free format text: FORMER NAME: OXO CHEMIE AG |
|
CP01 | Change in the name or title of a patent holder |
Address after: Fribourg Patentee after: Dimi Said Ltd Address before: Fribourg Patentee before: Oxo Chemie AG |
|
C56 | Change in the name or address of the patentee |
Owner name: NOVO RESEARCH CO., LTD. Free format text: FORMER NAME: DIMISIDE LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Fribourg Patentee after: Nouveau Research Co. Ltd. Address before: Fribourg Patentee before: Dimi Said Ltd |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040609 Termination date: 20141006 |
|
EXPY | Termination of patent right or utility model |